1. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow
- Author
-
Bikdeli, B, Madhavan, MV, Jimenez, D, Chuich, T, Dreyfus, I, Driggin, E, Der Nigoghossian, C, Ageno, W, Madjid, M, Guo, YT, Tang, LV, Hu, Y, Giri, J, Cushman, M, Quere, I, Dimakakos, EP, Gibson, CM, Lippi, G, Favaloro, EJ, Fareed, J, Caprini, JA, Tafur, AJ, Burton, JR, Francese, DP, Wang, EY, Falanga, A, McLintock, C, Hunt, BJ, Spyropoulos, AC, Barnes, GD, Eikelboom, JW, Weinberg, I, Schulman, S, Carrier, M, Piazza, G, Beckman, JA, Steg, G, Stone, GW, Rosenkranz, S, Goldhaber, SZ, Parikh, SA, Monreal, M, Krumholz, HM, Konstantinides, SV, Weitz, JI, and Lip, GYH
- Abstract
Coronavirus disease-2019 (COVID-19), a viral respiratory illness caused by the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), may predispose patients to thrombotic disease, both in the venous and arterial circulations, because of excessive inflammation, platelet activation, endothelial dysfunction, and stasis. In addition, many patients receiving antithrombotic therapy for thrombotic disease may develop COVID-19, which can have implications for choice, dosing, and laboratory monitoring of antithrombotic therapy. Moreover, during a time with much focus on COVID-19, it is critical to consider how to optimize the available technology to care for patients without COVID-19 who have thrombotic disease. Herein, the authors review the current understanding of the pathogenesis, epidemiology, management, and outcomes of patients with COVID-19 who develop venous or arterial thrombosis, of those with pre-existing thrombotic disease who develop COVID-19, or those who need prevention or care for their thrombotic disease during the COVID-19 pandemic. (J Am Coll Cardiol 2020;75:2950-73) (c) 2020 by the American College of Cardiology Foundation.
- Published
- 2020